<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">15161012</PMID>
        <DateCompleted>
            <Year>2004</Year>
            <Month>07</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0250-7005</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>24</Volume>
                    <Issue>2B</Issue>
                    <PubDate>
                        <MedlineDate>2004 Mar-Apr</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Relationship between differentiation-inducing activity and hypercalcemic activity of hexafluorotrihydroxyvitamin D3 derivatives.</ArticleTitle>
            <Pagination>
                <MedlinePgn>683-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Among 16 newly synthesized hexafluorotrihydroxyvitamin D3 derivatives, 24-Homo-26,26,26,27,27,27-hexafluoro (24H-F6)-1,24(S), 25(OH)3 vitamin D3 (VD3) (DD-011) [16] induced differentiation (i.e., appearance of NBT-positive cells) of human promyelocytic leukemic HL-60 cells most efficiently (EC50=0.5 nM), followed by 24H-F6-1,25(OH)2-22-oxa-VD3 (DD-006) [11] &gt; F6-1,25(OH)2-VD3 (F6VD3) [2] &gt; F6-1,25(OH)2-22-ene-VD3 (DD-009) [14] &gt; 24H-F6-1,25(OH)2-VD3 (F6C28) [3] &gt; 24H-F6-1,25(OH)2-1,23(S),25(OH)3-VD3 (DD-015) [18] &gt; 24H-F6-1,25(OH)2-22-ene-VD3 (mvd1400) [6] &gt; 22H-F6-1,25(OH)2-24-ene-VD3 (mvd3400) [5] &gt; 24H-F6-1,23(R),25(OH)3-VD3 (DD-014) [17] &gt; 24H-F6-1,22(S),25(OH)3-VD3 (DD-003) [7] &gt; 24H-F6-1,22(S),25(OH)3-24-yne-VD3 (DD-005) [9] &gt; 24H-F6-1,22(R),25(OH)3-24-yne-VD3 (mvd-1235) [10] &gt; F6-1,25(OH)2-22-ene-VD3 (DD-008) [13] = 1,25(OH)2VD3 [1] (CC50=6 nM). On the other hand, 24H-F6-1,22(R),25(OH)3-VD3 (DD-004) [8], which is an isomer of DD-003 [7], showed much reduced activity (CC50=100 nM), suggesting the importance of the configuration of the OH group at the C-22. When their differentiation-inducing activity was plotted vs. the octanol-water partition coefficient (log P) used as a parameter of hydrophobicity, a bell-shaped curve was produced, with the bottom at log P=5.4-5.8. There was no clear-cut relationship between the differentiation-inducing activity and hypercalcemic activity (serum calcium elevating activity). Compounds [3, 7, 11, 17] showed relatively higher differentiation-inducing activity, with lesser hypercalcemic activity, as compared with [1]. Administration of [7] showed potent antiproliferation activity against colon cancer transplanted in nude mice. These results further confirmed the antitumor potential of hexafluorotrihydroxyvitamin D3 derivatives.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Unten</LastName>
                    <ForeName>Senwa</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dental Pharmacology, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ishihara</LastName>
                    <ForeName>Mariko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakagami</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1C6V77QF41</RegistryNumber>
                <NameOfSubstance UI="D002762">Cholecalciferol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002762" MajorTopicYN="N">Cholecalciferol</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018922" MajorTopicYN="N">HL-60 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006845" MajorTopicYN="N">Hydrocarbons, Fluorinated</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006934" MajorTopicYN="N">Hypercalcemia</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>7</Month>
                <Day>20</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15161012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>